ReviewJournal of immunotherapy (Hagerstown, Md. : 1997)
Immunotherapy for melanoma: current status and perspectives.
Review in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Stem cell tracking in human trials: a meta-regression.Stem cell reviews and reports · 2011Pooled it
- Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.Pathology oncology research : POR · 2014Trial
- Pharmacological Properties of 4', 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways.Molecules (Basel, Switzerland) · 2022Review
- Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation.Oncology letters · 2020Article
- Interference from LncRNA SPRY4-IT1 restrains the proliferation, migration, and invasion of melanoma cells through inactivating MAPK pathway by up-regulating miR-22-3p.International journal of clinical and experimental pathology · 2019Article
- NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12.Gastroenterology · 2018Article
- Preventive, predictive, and personalized medicine for effective and affordable cancer care.The EPMA journal · 2018Review
- SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma.Journal of cancer research and clinical oncology · 2018Article
- Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.Journal of cellular biochemistry · 2018Article
- New trends in antitumor vaccines in melanoma.Annals of translational medicine · 2017Review
- Indicators of responsiveness to immune checkpoint inhibitors.Scientific reports · 2017Article
- Apigenin in cancer therapy: anti-cancer effects and mechanisms of action.Cell & bioscience · 2017Review
- Differential expression of TYRP1 in adult human retinal pigment epithelium and uveal melanoma cells.Oncology letters · 2016Article
- Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.Oncotarget · 2016Article
- Regulatory T cells in the immunotherapy of melanoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.International journal of cancer · 2015Article
- Increased survival time of a patient with metastatic malignant melanoma following immunotherapy: A case report and literature review.Oncology letters · 2015Article
- Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy.Journal of translational medicine · 2014Article
- Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Melanoma immunotherapy.Cancer biology & therapy · 2014Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Immunotherapy is an important modality in the therapy of patients with malignant melanoma. As our knowledge about this disease continues to expand, so does the immunotherapeutic armamentarium. Nevertheless, successful preclinical models do not always translate into clinically meaningful results. The authors give a comprehensive analysis of most recent advances in the immune anti-melanoma therapy, including interleukins, interferons, other cytokines, adoptive immunotherapy, biochemotherapy, as well as the use of different vaccines. We also present the fundamental concepts behind various immune enhancement strategies, passive immunotherapy, as well as the use of immune adjuvants. This review brings into discussion the results of newer and older clinical trials, as well as potential limitations and drawbacks seen with the utilization of various immune therapies in malignant melanoma. Development of novel therapeutic approaches, along with optimization of existing therapies, continues to hold a great promise in the field of melanoma therapy research. Use of anti-CTLA4 and anti-PD1 antibodies, realization of the importance of co-stimulatory signals, which translated into the use of agonist CD40 monoclonal antibodies, as well as activation of innate immunity through enhanced expression of co-stimulatory molecules on the surface of dendritic cells by TLR agonists are only a few items on the list of recent advances in the treatment of melanoma. The need to engineer better immune interactions and to boost positive feedback loops appear crucial for the future of melanoma therapy, which ultimately resides in our understanding of the complexity of immune responses in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.